Aspire Biopharma Holdings Inc.

Aspire Biopharma Holdings Inc. is an early-stage biopharmaceutical company focused on developing and marketing innovative drug delivery technologies. Established in 2021 and headquartered in Humacao, Puerto Rico, the company’s core mission centers on creating advanced delivery mechanisms for "do no harm" drugs, aiming to enhance patient outcomes and drug efficacy. Notably, Aspire Biopharma has developed a sublingual aspirin product designed for rapid response in cardiology emergencies and pain management scenarios. In addition to this flagship product, the company is working on sublingual formulations for a diverse range of applications, including melatonin sleep aids, vitamins D, E, and K, testosterone, semaglutide, as well as therapeutics for anti-nausea, antipsychotic, erectile dysfunction, and seizure indications. Aspire Biopharma’s approach leverages patent-pending technologies to support fast-acting, patient-friendly drug administration, contributing to the advancement of drug delivery science within the healthcare sector. The company recently completed a business combination, positioning itself for expanded clinical development and commercial activities in the United States.